TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
Epistemonikos ID: 914a04e13102f815e8077c564444ebef5cb20341
First added on: May 04, 2024